Middle East & Africa Overactive Bladder Treatment Market Forecast to 2028 - COVID-19 Impact and Regional Analysis

Description

List of Tables

The Middle East & Africa overactive bladder treatment market is expected to grow from US$ 290.94 million in 2022 to US$ 330.17 million by 2028; it is estimated to grow at a CAGR of 2.1% from 2022 to 2028.

Increasing Number of Mergers and Acquisitions to Fuel Middle East & Africa Overactive Bladder Treatment Market in Coming Years

Through mergers and acquisitions (M&A), companies can gain a competitive edge by entering new markets and acquiring new technologies. The ongoing mergers and acquisitions in the overactive bladder treatment market are creating growth opportunities for various companies. In July 2021, Uro Medical strengthened its urology portfolio with the acquisition of Micron Medical, which offers wirelessly powered, injectable, microtechnology neurostimulators focused on treating overactive bladder. These neurostimulators, which can be easily incorporated into patients' daily lives, offer a convenient, safe, minimally invasive, and cost-effective urological treatment option. In February 2021, Axonics Modulation Technologies, Inc.-a medical technology company-acquired Contura Ltd. and its proprietary product, Bulkamid, which is a urethral bulking agent for women with stress urinary incontinence (SUI). Axonics produces and markets novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction. The acquisition of Contura Ltd. provides an opportunity to expand its SNM business across the world and serve the large, highly underpenetrated SUI market. The company plans to offer urogynecologists and urologists a complete suite of clinically differentiated incontinence solutions to treat their patients. Thus, increasing number of mergers and acquisitions is propelling Middle East & Africa overactive bladder treatment market growth.

Middle East & Africa Overactive Bladder Treatment Market Overview

The Middle East & Africa overactive bladder treatment market is segmented into the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa. The market growth is attributed to the increasing prevalence of chronic diseases and growing medical research studies across the region. Urinary incontinence is a clinical condition that is observed more among women in Saudi Arabia. According to The Cureus Journal of Medical Science published in the National Library of Medicine, in 2022, the prevalence of urinary continence in Jeddah and Riyadh, Saudi Arabia, was estimated to be 41.4% and 29%, respectively. A few factors such as age, obesity, medical comorbidities, hysterectomy, and multiparity contribute to the occurrence of urinary incontinence condition. Further, multiple pregnancy cases and rise in the geriatric population are also a few factors contributing to the growth of the overactive bladder treatment market. Also, the rise in the prevalence of chronic diseases and the high demand for rapid diagnosis, effective treatment options, and preventive measures are boosting the market growth in Saudi Arabia. The Saudi Arabia Ministry of Health provides primary health services through 2,259 centers to ~13,455 people. The primary health center settings are the first in line that deals with emerging complaints such as urological-related problems. It helps assess knowledge and practice patterns regarding common urological problems observed by primary health centers physicians. Thus, aforementioned factors are anticipated to fuel the growth of the overactive bladder treatment market in the coming years.

Middle East & Africa Overactive Bladder Treatment Market Revenue and Forecast to 2028 (US$ Million)

Middle East & Africa Overactive Bladder Treatment Market Segmentation

The Middle East & Africa overactive bladder treatment market is segmented on the basis of pharmacotherapy, disease type, and country.

Based on pharmacotherapy, the Middle East & Africa overactive bladder treatment market is segmented into anticholinergics, mirabegron, botox, neurostimulation, and intravesical instillation. The mirabegron segment registered the largest share of the market in 2022.

Based on disease type, the Middle East & Africa overactive bladder treatment market is bifurcated into idiopathic overactive bladder and neurogenic bladder. The idiopathic overactive bladder segment held a larger share of the market in 2022.

Based on country, the Middle East & Africa overactive bladder treatment market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Saudi Arabia dominated the market in 2022.

AbbVie Inc; Alembic Pharmaceuticals Limited; Astellas Pharma Inc; Endo Pharmaceuticals Inc.; Hisamitsu Pharmaceutical Co., Inc.; Medtronic Plc; Pfizer Inc; and Teva Pharmaceutical Industries Ltd are the leading companies operating in the Middle East & Africa overactive bladder treatment market.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Middle East & Africa overactive bladder treatment market
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the Middle East & Africa overactive bladder treatment market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth Middle East & Africa market trends and outlook coupled with the factors driving the overactive bladder treatment market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution

Product Code: BMIRE00027936

1. Introduction

1.1 Study Scope
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
- 1.3.1 MEA Overactive Bladder Treatment Market- By Pharmacotherapy
- 1.3.2 MEA Overactive Bladder Treatment Market- By Disease Type
- 1.3.3 MEA Overactive Bladder Treatment Market - By Country

2. MEA Overactive Bladder Treatment Market - Key Takeaways

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. MEA Overactive Bladder Treatment Market - Market Landscape

4.1 Overview
4.2 MEA PEST Analysis
4.3 Expert Opinion

5. MEA Overactive Bladder Treatment Market - Key Market Dynamics

5.1 Market Drivers
- 5.1.1 Increase in Prevalence of Urinary Incontinence
- 5.1.2 Growing Incidence of Urinary Tract Infections
5.2 Key Market Restraints
- 5.2.1 Recalls of Therapeutic Drugs
5.3 Key Market Opportunities
- 5.3.1 Increasing Number of Mergers and Acquisitions
5.4 Future Trends
- 5.4.1 Robust Pipeline of Drugs and Successive Launch of Novel Therapies
5.5 Impact analysis

6. MEA Overactive Bladder Treatment Market - MEA Analysis

6.1 MEA Overactive Bladder Treatment Market Revenue Forecast and Analysis

7. MEA Overactive Bladder Treatment Market Analysis and Forecasts To 2028 - By Pharmacotherapy

7.1 Overview
7.2 MEA Overactive Bladder Treatment Market, By Pharmacotherapy 2021 & 2028 (%)
7.3 Mirabegron
- 7.3.1 Overview
- 7.3.2 Mirabegron: MEA Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
7.4 Botox
- 7.4.1 Overview
- 7.4.2 Botox: MEA Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
7.5 Neurostimulation
- 7.5.1 Overview
- 7.5.2 Neurostimulation: MEA Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
- 7.5.3 Transcutaneous Sacral Nerve Stimulation
  - 7.5.3.1 Overview
  - 7.5.3.2 Transcutaneous Sacral Nerve Stimulation: MEA Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
- 7.5.4 Transcutaneous Tibial Nerve Stimulation
  - 7.5.4.1 Overview
  - 7.5.4.2 Transcutaneous Tibial Nerve Stimulation: MEA Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
- 7.5.5 Percutaneous Posterior Tibial Nerve Stimulation
  - 7.5.5.1 Overview
  - 7.5.5.2 Percutaneous Posterior Tibial Nerve Stimulation: MEA Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
- 7.5.6 Others
  - 7.5.6.1 Overview
  - 7.5.6.2 Others: MEA Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
7.6 Anticholinergics
- 7.6.1 Overview
- 7.6.2 Anticholinergics: MEA Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
- 7.6.3 Solifenacin
  - 7.6.3.1 Overview
  - 7.6.3.2 Solifenacin: MEA Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
- 7.6.4 Oxybutynin
  - 7.6.4.1 Overview
  - 7.6.4.2 Oxybutynin: MEA Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
- 7.6.5 Fesoterodine
  - 7.6.5.1 Overview
  - 7.6.5.2 Fesoterodine: MEA Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
- 7.6.6 Darifenacin
  - 7.6.6.1 Overview
  - 7.6.6.2 Darifenacin: MEA Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
- 7.6.7 Tolterodine
  - 7.6.7.1 Overview
  - 7.6.7.2 Tolterodine: MEA Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
- 7.6.8 Trospium
  - 7.6.8.1 Overview
  - 7.6.8.2 Trospium: MEA Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
- 7.6.9 Other Anticholinergics
  - 7.6.9.1 Overview
  - 7.6.9.2 Other Anticholinergics: MEA Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
7.7 Intravesical Instillation
- 7.7.1 Overview
- 7.7.2 Intravesical Instillation: MEA Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)

8. MEA Overactive Bladder Treatment Market Analysis and Forecasts To 2028 - By Disease Type

8.1 Overview
8.2 MEA Overactive Bladder Treatment Market, By Disease Type 2021 & 2028 (%)
8.3 Idiopathic Overactive Bladder
- 8.3.1 Overview
- 8.3.2 Idiopathic: MEA Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
8.4 Neurogenic Overactive Bladder
- 8.4.1 Overview
- 8.4.2 Neurogenic: Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)

9. Overactive Bladder Treatment Market Revenue and Forecasts to 2028 - Country Analysis

9.1 Overview
- 9.1.1 MEA: Overactive Bladder Treatment Market, by Country, 2021 & 2028 (%)
  - 9.1.1.1 UAE: overactive bladder treatment Market - Revenue and Forecast to 2028 (USD Million)
    - 9.1.1.1.1 UAE: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
    - 9.1.1.1.2 UAE: Overactive Bladder Treatment Market, by Pharmacotherapy, 2019-2028 (US$ Million)
    - 9.1.1.1.2.1 UAE: Overactive Bladder Treatment Market, by Anticholinergic, 2019-2028 (US$ Million)
    - 9.1.1.1.2.2 UAE Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (USD Million)
    - 9.1.1.1.3 UAE: Overactive Bladder Treatment Market, by Disease Type, 2019-2028 (US$ Million)
  - 9.1.1.2 Saudi Arabia: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
    - 9.1.1.2.1 Saudi Arabia: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
    - 9.1.1.2.2 Saudi Arabia: Overactive Bladder Treatment Market, by Pharmacotherapy, 2019-2028 (US$ Million)
    - 9.1.1.2.2.1 Saudi Arabia: Overactive Bladder Treatment Market, by Anticholinergic, 2019-2028 (US$ Million)
    - 9.1.1.2.2.2 Saudi Arabia Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (USD Million)
    - 9.1.1.2.3 Saudi Arabia: Overactive Bladder Treatment Market, by Disease Type, 2019-2028 (US$ Million)
  - 9.1.1.3 South Africa: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (USD Million)
    - 9.1.1.3.1 South Africa: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
    - 9.1.1.3.2 South Africa: Overactive Bladder Treatment Market, by Pharmacotherapy, 2019-2028 (US$ Million)
    - 9.1.1.3.2.1 South Africa: Overactive Bladder Treatment Market, by Anticholinergic, 2019-2028 (US$ Million)
    - 9.1.1.3.2.2 South Africa Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (USD Million)
    - 9.1.1.3.3 South Africa: Overactive Bladder Treatment Market, by Disease Type, 2019-2028 (US$ Million)
  - 9.1.1.4 Rest of MEA: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
    - 9.1.1.4.1 Rest of MEA: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
    - 9.1.1.4.2 Rest of MEA: Overactive Bladder Treatment Market, by Pharmacotherapy, 2019-2028 (US$ Million)
    - 9.1.1.4.2.1 Rest of MEA: Overactive Bladder Treatment Market, by Anticholinergic, 2019-2028 (US$ Million)
    - 9.1.1.4.2.2 Rest of MEA Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (USD Million)
    - 9.1.1.4.3 Rest of MEA: Overactive Bladder Treatment Market, by Disease Type, 2019-2028 (US$ Million)

10. Overactive Bladder Treatment Market- Industry Landscape

10.1 Overview
10.2 Organic Developments
- 10.2.1 Overview

11. Company Profiles

11.1 Alembic Pharmaceuticals Limited
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Astellas Pharma Inc
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 AbbVie Inc
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Teva Pharmaceutical Industries Ltd
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Endo Pharmaceuticals Inc.
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Hisamitsu Pharmaceutical Co., Inc.
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Medtronic Plc
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Pfizer Inc
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments

12. Appendix

12.1 About The Insight Partners
12.2 Glossary of Terms